Business
Aurinia to Participate in Upcoming Investor Healthcare Conferences
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s
About this update from Aurinia Pharmaceuticals Inc
[{"type":"text","content":" ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--\nAurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will participate in one-on-one meetings with investors at the Leerink Partners Therapeutics Forum: I&I and Metabolism, July 9-10, 2024, in Boston, and at the 3rd Annual H.C. Wainwright Virtual Kidney Conference, July 15, 2024.\n\n\nAbout Aurinia\n\n\nAurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company’s head office is in Edmonton, Alberta, its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts globally.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240702079714/en/\n\nMedia and Investor Inquiries:\nAndrea Christopher\nCorporate Communications and Investor Relations, Aurinia\[email protected]\[email protected]\n\n\nSource: Aurinia Pharmaceuticals Inc.","length":2436,"tagName":"div"}]